Marcin Kortylewski: Difference between revisions

Marcin Kortylewski
Marcin Kortylewski
Born	Poznań, Poland
Years active	1996–present
Academic background
Alma mater	Adam Mickiewicz University
Academic work
Institutions	Poznań University of Medical Sciences RWTH Aachen University H. Lee Moffitt Cancer Center & Research Institute City of Hope National Medical Center
Website	https://www.linkedin.com/in/marcin-kortylewski-6841b220/

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 15:11, 4 January 2024

Marcin Kortylewski is a Polish American cancer researcher and immunologist. He is currently professor of immuno-oncology at the Beckman Research Institute of the City of Hope National Medical Center in Duarte, California.^[1] His research has shown that the STAT3 protein plays a role in protecting cancers from immune responses and contributes to resistance to therapies.^[2]^[3] Later he developed a two-pronged strategy for cancer immunotherapy using simultaneous STAT3 inhibition and TLR9 immune stimulation.^[4]^[5]^[6] Kortylewski invented platform strategy for delivery of oligonucleotides, such as siRNA,^[7] miRNA,^[8] decoy DNA,^[6]^[9] antisense molecules^[10] and others to selected immune cells.

Education

Kortylewski was born in Poznań, Poland. He received his M.S. in biotechnology from Adam Mickiewicz University and his Ph.D. in molecular biology from the Poznań University of Medical Sciences in Poznań, Poland.^[1]^[11] Dr. Kortylewski completed postdoctoral training in cancer biology in Institute of Biochemistry at RWTH Aachen in Germany and later in tumor immunology at H. Lee Moffitt Cancer Center in Tampa, Florida in USA.^[1]

Career

Kortylewski began his post-graduate career in 1999 as a postdoctoral fellow in Iris Behrman’s lab in RWTH Aachen/Institute of Biochemistry chaired by Peter C. Heinrich. During his tenure there, he co-authored numerous research articles.^[12] Later, he moved to H. Lee Moffitt Cancer Center in Tampa, Florida in USA to train with Richard Jove and Hua Yu. In 2005, he became Assistant Research Professor in the Beckman Research Institute of the City of Hope National Medical Center in Duarte, California. There, he became tenured faculty in 2010 and full professor at the Department of Immuno-Oncology in 2021.^{[citation needed]}

Kortylewski's research group focuses on understanding the mechanisms by which cancers evade the immune system and explores methods to enhance antitumor immune responses using DNA and RNA-based drugs.^[1]^[13]^[14] In early 2000s, he demonstrated that tumors turn off immune cell activity using a transcription factor, STAT3.^[3] His studies characterized STAT3 as a multitasking protein which prevents immune activation, while stimulating tumor vascularization and metastasis.^[5]^[2] Kortylewski invented a two-pronged strategy for cancer immunotherapy combining STAT3 blocking using siRNA with triggering of immune receptor, Toll-like receptor 9 (TLR9) using CpG motif DNA.^[15]^[7]^[16] Later on, he adopted the strategy as a platform for delivery of various oligonucleotide drugs to target oncogenic or immune regulators, such as STAT3, NF-kB or selected miRNAs^[17]^[18]^[19] in human or mouse immune cells in vivo.

Kortylewski is a co-founder of a biomedical startup company, currently under the name Duet Biotherapeutics Inc., focused on advancing CpG-STAT3 inhibitors to clinical trials for cancer immunotherapy.^[20]^[21] He is an active contributor to the field of immune-oncology and oligonucleotide therapeutics, serving on scientific and editorial boards of journals and various organizations.^[22]^[23]^[24]

Awards

In 2016, Kortylewski was a recipient of an Outstanding Young Investigator Award from American Society of Gene and Cell Therapy, granted based on the contributions to the field of gene and cell therapy.^[25] He received the award specifically for his work on “Eliminating Tumor Immune Defenses using Oligonucleotide Therapeutics”.

Patents


Patent Number	Patent Name
US 9,688,982 US 10,253,318	Methods and compositions for the treatment of cancer or other diseases
US 9,976,147 US 10,829,765	STAT3 inhibitors and uses thereof
US 10,758,624	Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US 10,711,272 US 11,186,840	CTLA-4 aptamer siRNA species CTLA-4 Aptamer Conjugates
US 10,801,026	Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

References

^ ^a ^b ^c ^d "Marcin Kortylewski, Ph.D." City of Hope. 2022-05-11. Retrieved 2023-09-04.
^ ^a ^b Minton, Kirsty (2009). "Multi-tasking by STAT3". Nature Reviews Immunology. 9 (3): 149. doi:10.1038/nri2517. ISSN 1474-1741.
^ ^a ^b Stewart, C. Andrew; Trinchieri, Giorgio (2009). "Reinforcing Suppression Using Regulators: A New Link between STAT3, IL-23, and Tregs in Tumor Immunosuppression". Cancer Cell. 15 (2): 81–83. doi:10.1016/j.ccr.2009.01.008.
^ Gantier, Michael P; Williams, Bryan R G (2009). "siRNA delivery not Toll-free". Nature Biotechnology. 27 (10): 911–912. doi:10.1038/nbt1009-911. ISSN 1087-0156.
^ ^a ^b "STAT3: the "Achilles" heel for AML?". ashpublications.org. Retrieved 2023-09-04.
^ ^a ^b "A STAT3 decoy lures AML out of hiding". ashpublications.org. Retrieved 2023-09-04.
^ ^a ^b Flemming, Alexandra (2009). "CpG–siRNA deals double blow to tumours". Nature Reviews Immunology. 9 (11): 753. doi:10.1038/nri2665. ISSN 1474-1733.
^ "MicroRNA immunomodulating therapeutics". ashpublications.org. Retrieved 2023-09-11.
^ Soldevilla, Mario M.; Pastor, Fernando (2018). "Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy". Molecular Therapy. 26 (3): 675–677. doi:10.1016/j.ymthe.2018.02.006. ISSN 1525-0016. PMC 5911647.
^ "STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers". aacrjournals.org. Retrieved 2023-09-11.
^ "BioSpace Movers & Shakers, Sept. 10". BioSpace. Retrieved 2023-09-22.
^ "kortylewski – Search Results – RWTH Publications". publications.rwth-aachen.de. Retrieved 2023-09-19.
^ Kortylewski, Marcin. "Marcin Kortylewski". ResearchGate.
^ "Marcin Kortylewski". scholar.google.com. Retrieved 2023-09-04.
^ slater, elias (2014-02-18). "Delivering a Triple-Knockout Punch to Prostate Cancer". Prostate Cancer Foundation. Retrieved 2023-09-11.
^ Gantier, Michael P; Williams, Bryan R G (2009). "siRNA delivery not Toll-free". Nature Biotechnology. 27 (10): 911–912. doi:10.1038/nbt1009-911. ISSN 1087-0156.
^ Meyer, Sara E. (2020-01-16). "MicroRNA immunomodulating therapeutics". Blood. 135 (3): 155–156. doi:10.1182/blood.2019004106. ISSN 0006-4971. PMC 6966931.
^ Su, Yu-Lin; Wang, Xiuli; Mann, Mati; Adamus, Tomasz P.; Wang, Dongfang; Moreira, Dayson F.; Zhang, Zhuoran; Ouyang, Ching; He, Xin; Zhang, Bin; Swiderski, Piotr M.; Forman, Stephen J.; Baltimore, David; Li, Ling; Marcucci, Guido (2020-01-16). "Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo". Blood. 135 (3): 167–180. doi:10.1182/blood.2019002045. ISSN 0006-4971. PMC 6966933.
^ Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling; Zhao, Dandan; Kumar, Bijender; Wu, Herman; Lin, Allen; Pellicano, Francesca; Hopcroft, Lisa; Su, Yu-Lin; Copland, Mhairi; Holyoake, Tessa L; Kuo, Calvin J; Bhatia, Ravi; Snyder, David S (2018). "Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia". Nature Medicine. 24 (4): 450–462. doi:10.1038/nm.4499. ISSN 1078-8956. PMC 5965294.
^ "Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune". www.sec.gov. Retrieved 2023-09-11.
^ Harris, William (2021-09-07). "Duet Therapeutics Appoints Marcin Kortylewski, Ph.D. as Senior Scientific Advisor". citybiz. Retrieved 2023-09-11.
^ Labant, MaryAnn (2014-06-15). "Therapeutic siRNA Interventions". Genetic Engineering & Biotechnology News. 34 (12): 1, 18–19. doi:10.1089/gen.34.12.01. ISSN 1935-472X.
^ Cell. "Molecular Therapy – Nucleic Acids editorial board contacts".
^ "SITC Communications Committee". www.sitcancer.org. Retrieved 2023-09-11.
^ "Outstanding New Investigator Awards | ASGCT – American Society of Gene & Cell Therapy | ASGCT – American Society of Gene & Cell Therapy". asgct.org. Retrieved 2023-09-04.

[:0-1] "Marcin Kortylewski, Ph.D." City of Hope. 2022-05-11. Retrieved 2023-09-04.

[:5-2] Minton, Kirsty (2009). "Multi-tasking by STAT3". Nature Reviews Immunology. 9 (3): 149. doi:10.1038/nri2517. ISSN 1474-1741.

[:4-3] Stewart, C. Andrew; Trinchieri, Giorgio (2009). "Reinforcing Suppression Using Regulators: A New Link between STAT3, IL-23, and Tregs in Tumor Immunosuppression". Cancer Cell. 15 (2): 81–83. doi:10.1016/j.ccr.2009.01.008.

[4] Gantier, Michael P; Williams, Bryan R G (2009). "siRNA delivery not Toll-free". Nature Biotechnology. 27 (10): 911–912. doi:10.1038/nbt1009-911. ISSN 1087-0156.

[:6-5] "STAT3: the "Achilles" heel for AML?". ashpublications.org. Retrieved 2023-09-04.

[:7-6] "A STAT3 decoy lures AML out of hiding". ashpublications.org. Retrieved 2023-09-04.

[:9-7] Flemming, Alexandra (2009). "CpG–siRNA deals double blow to tumours". Nature Reviews Immunology. 9 (11): 753. doi:10.1038/nri2665. ISSN 1474-1733.

[8] "MicroRNA immunomodulating therapeutics". ashpublications.org. Retrieved 2023-09-11.

[9] Soldevilla, Mario M.; Pastor, Fernando (2018). "Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy". Molecular Therapy. 26 (3): 675–677. doi:10.1016/j.ymthe.2018.02.006. ISSN 1525-0016. PMC 5911647.

[10] "STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers". aacrjournals.org. Retrieved 2023-09-11.

[11] "BioSpace Movers & Shakers, Sept. 10". BioSpace. Retrieved 2023-09-22.

[12] "kortylewski – Search Results – RWTH Publications". publications.rwth-aachen.de. Retrieved 2023-09-19.

[:2-13] Kortylewski, Marcin. "Marcin Kortylewski". ResearchGate.

[:3-14] "Marcin Kortylewski". scholar.google.com. Retrieved 2023-09-04.

[15] slater, elias (2014-02-18). "Delivering a Triple-Knockout Punch to Prostate Cancer". Prostate Cancer Foundation. Retrieved 2023-09-11.

[16] Gantier, Michael P; Williams, Bryan R G (2009). "siRNA delivery not Toll-free". Nature Biotechnology. 27 (10): 911–912. doi:10.1038/nbt1009-911. ISSN 1087-0156.

[17] Meyer, Sara E. (2020-01-16). "MicroRNA immunomodulating therapeutics". Blood. 135 (3): 155–156. doi:10.1182/blood.2019004106. ISSN 0006-4971. PMC 6966931.

[:10-18] Su, Yu-Lin; Wang, Xiuli; Mann, Mati; Adamus, Tomasz P.; Wang, Dongfang; Moreira, Dayson F.; Zhang, Zhuoran; Ouyang, Ching; He, Xin; Zhang, Bin; Swiderski, Piotr M.; Forman, Stephen J.; Baltimore, David; Li, Ling; Marcucci, Guido (2020-01-16). "Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo". Blood. 135 (3): 167–180. doi:10.1182/blood.2019002045. ISSN 0006-4971. PMC 6966933.

[:11-19] Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling; Zhao, Dandan; Kumar, Bijender; Wu, Herman; Lin, Allen; Pellicano, Francesca; Hopcroft, Lisa; Su, Yu-Lin; Copland, Mhairi; Holyoake, Tessa L; Kuo, Calvin J; Bhatia, Ravi; Snyder, David S (2018). "Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia". Nature Medicine. 24 (4): 450–462. doi:10.1038/nm.4499. ISSN 1078-8956. PMC 5965294.

[20] "Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune". www.sec.gov. Retrieved 2023-09-11.

[21] Harris, William (2021-09-07). "Duet Therapeutics Appoints Marcin Kortylewski, Ph.D. as Senior Scientific Advisor". citybiz. Retrieved 2023-09-11.

[22] Labant, MaryAnn (2014-06-15). "Therapeutic siRNA Interventions". Genetic Engineering & Biotechnology News. 34 (12): 1, 18–19. doi:10.1089/gen.34.12.01. ISSN 1935-472X.

[23] Cell. "Molecular Therapy – Nucleic Acids editorial board contacts".

[24] "SITC Communications Committee". www.sitcancer.org. Retrieved 2023-09-11.

[25] "Outstanding New Investigator Awards | ASGCT – American Society of Gene & Cell Therapy | ASGCT – American Society of Gene & Cell Therapy". asgct.org. Retrieved 2023-09-04.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

@@ Line 1: / Line 1: @@
+{{Short description|Polish American cancer researcher and immunologist}}
-{{Multiple issues|
-{{Primary sources|date=September 2023}}
-{{Orphan|date=September 2023}}
-}}
 {{Infobox academic
 | name = Marcin Kortylewski
@@ Line 11: / Line 8: @@
 H. Lee Moffitt Cancer Center & Research Institute
 City of Hope National Medical Center
-| period = 1996-present
+| period = 1996–present
 | website = https://www.linkedin.com/in/marcin-kortylewski-6841b220/
 | image = MK headshot 2022 small.jpg
@@ Line 17: / Line 14: @@
 }}
-'''Marcin Kortylewski''' is a Polish American cancer researcher and immunologist. He is currently professor of immuno-oncology at the [[Beckman Research Institute]] of the [[City of Hope National Medical Center]] in [[Duarte, California]].<ref name=":0">{{Cite web |date=2022-05-11 |title=Marcin Kortylewski, Ph.D. |url=https://www.cityofhope.org/marcin-kortylewski |access-date=2023-09-04 |website=City of Hope |language=en}}</ref><ref name=":2">{{Cite web |last=Kortylewski |first=Marcin |title=Marcin Kortylewski |url=https://www.researchgate.net/profile/Marcin-Kortylewski/6 |url-status=live |access-date= |website=ResearchGate}}</ref><ref name=":3">{{Cite web |title=Marcin Kortylewski |url=https://scholar.google.com/citations?user=jSwLiswAAAAJ&hl=en |access-date=2023-09-04 |website=scholar.google.com}}</ref> His research has shown that the STAT3 protein plays a role in protecting cancers from immune responses and contributes to resistance to therapies.<ref name=":1">{{Cite journal |last=Yu |first=Hua |last2=Kortylewski |first2=Marcin |last3=Pardoll |first3=Drew |date=2007-01-01 |title=Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment |url=https://www.nature.com/articles/nri1995 |journal=Nature Reviews Immunology |language=en |volume=7 |issue=1 |pages=41–51 |doi=10.1038/nri1995 |issn=1474-1733}}</ref><ref name=":5">{{Cite journal |last=Minton |first=Kirsty |title=Multi-tasking by STAT3 |url=https://www.nature.com/articles/nri2517 |journal=Nature Reviews Immunology |language=en |volume=9 |issue=3 |pages=149–149 |doi=10.1038/nri2517 |issn=1474-1741}}</ref><ref name=":4">{{Cite journal |last=Stewart |first=C. Andrew |last2=Trinchieri |first2=Giorgio |title=Reinforcing Suppression Using Regulators: A New Link between STAT3, IL-23, and Tregs in Tumor Immunosuppression |url=https://linkinghub.elsevier.com/retrieve/pii/S1535610809000051 |journal=Cancer Cell |language=en |volume=15 |issue=2 |pages=81–83 |doi=10.1016/j.ccr.2009.01.008}}</ref>. Later he developed a two-pronged strategy for cancer immunotherapy using simultaneous STAT3 inhibition and TLR9 immune stimulation.<ref>{{Cite journal |last=Gantier |first=Michael P |last2=Williams |first2=Bryan R G |title=siRNA delivery not Toll-free |url=https://www.nature.com/articles/nbt1009-911 |journal=Nature Biotechnology |language=en |volume=27 |issue=10 |pages=911–912 |doi=10.1038/nbt1009-911 |issn=1087-0156}}</ref><ref name=":15">{{Cite journal |last=Kortylewski |first=Marcin |last2=Swiderski |first2=Piotr |last3=Herrmann |first3=Andreas |last4=Wang |first4=Lin |last5=Kowolik |first5=Claudia |last6=Kujawski |first6=Maciej |last7=Lee |first7=Heehyoung |last8=Scuto |first8=Anna |last9=Liu |first9=Yong |last10=Yang |first10=Chunmei |last11=Deng |first11=Jiehui |last12=Soifer |first12=Harris S |last13=Raubitschek |first13=Andrew |last14=Forman |first14=Stephen |last15=Rossi |first15=John J |title=In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses |url=https://www.nature.com/articles/nbt.1564 |journal=Nature Biotechnology |language=en |volume=27 |issue=10 |pages=925–932 |doi=10.1038/nbt.1564 |issn=1087-0156}}</ref><ref name=":6">{{Cite web |title=STAT3: the “Achilles” heel for AML? |url=https://ashpublications.org/blood/article/123/1/1/32121/STAT3-the-Achilles-heel-for-AML |access-date=2023-09-04 |website=ashpublications.org}}</ref><ref name=":7">{{Cite web |title=A STAT3 decoy lures AML out of hiding |url=https://ashpublications.org/blood/article/127/13/1628/34769/A-STAT3-decoy-lures-AML-out-of-hiding |access-date=2023-09-04 |website=ashpublications.org}}</ref> Kortylewski invented platform strategy for delivery of oligonucleotides<ref>{{Cite journal |last=Kortylewski |first=Marcin |last2=Moreira |first2=Dayson |title=Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities |url=http://link.springer.com/10.1007/s00262-017-1966-2 |journal=Cancer Immunology, Immunotherapy |language=en |volume=66 |issue=8 |pages=979–988 |doi=10.1007/s00262-017-1966-2 |issn=0340-7004}}</ref>, such as siRNA<ref name=":8">{{Cite journal |last=Nechaev |first=Sergey |last2=Gao |first2=Chan |last3=Moreira |first3=Dayson |last4=Swiderski |first4=Piotr |last5=Jozwiak |first5=Agnieszka |last6=Kowolik |first6=Claudia M. |last7=Zhou |first7=Jiehua |last8=Armstrong |first8=Brian |last9=Raubitschek |first9=Andrew |last10=Rossi |first10=John J. |last11=Kortylewski |first11=Marcin |title=Intracellular processing of immunostimulatory CpG–siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape |url=https://linkinghub.elsevier.com/retrieve/pii/S0168365913003416 |journal=Journal of Controlled Release |language=en |volume=170 |issue=3 |pages=307–315 |doi=10.1016/j.jconrel.2013.06.007 |pmc=3742675 |pmid=23777886}}</ref><ref>{{Cite journal |last=Zhang |first=Qifang |last2=Hossain |first2=Dewan Md Sakib |last3=Nechaev |first3=Sergey |last4=Kozlowska |first4=Anna |last5=Zhang |first5=Wang |last6=Liu |first6=Yong |last7=Kowolik |first7=Claudia M. |last8=Swiderski |first8=Piotr |last9=Rossi |first9=John J. |last10=Forman |first10=Stephen |last11=Pal |first11=Sumanta |last12=Bhatia |first12=Ravi |last13=Raubitschek |first13=Andrew |last14=Yu |first14=Hua |last15=Kortylewski |first15=Marcin |date=2013-02-21 |title=TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo |url=https://ashpublications.org/blood/article/121/8/1304/138832/TLR9mediated-siRNA-delivery-for-targeting-of |journal=Blood |language=en |volume=121 |issue=8 |pages=1304–1315 |doi=10.1182/blood-2012-07-442590 |issn=0006-4971}}</ref><ref name=":9">{{Cite journal |last=Flemming |first=Alexandra |title=CpG–siRNA deals double blow to tumours |url=https://www.nature.com/articles/nri2665 |journal=Nature Reviews Immunology |language=en |volume=9 |issue=11 |pages=753–753 |doi=10.1038/nri2665 |issn=1474-1733}}</ref>, miRNA<ref>{{Cite web |title=MicroRNA immunomodulating therapeutics |url=https://ashpublications.org/blood/article/135/3/155/430078/MicroRNA-immunomodulating-therapeutics |access-date=2023-09-11 |website=ashpublications.org}}</ref><ref name=":10">{{Cite journal |last=Su |first=Yu-Lin |last2=Wang |first2=Xiuli |last3=Mann |first3=Mati |last4=Adamus |first4=Tomasz P. |last5=Wang |first5=Dongfang |last6=Moreira |first6=Dayson F. |last7=Zhang |first7=Zhuoran |last8=Ouyang |first8=Ching |last9=He |first9=Xin |last10=Zhang |first10=Bin |last11=Swiderski |first11=Piotr M. |last12=Forman |first12=Stephen J. |last13=Baltimore |first13=David |last14=Li |first14=Ling |last15=Marcucci |first15=Guido |date=2020-01-16 |title=Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo |url=https://ashpublications.org/blood/article/135/3/167/429548/Myeloid-celltargeted-miR146a-mimic-inhibits |journal=Blood |language=en |volume=135 |issue=3 |pages=167–180 |doi=10.1182/blood.2019002045 |issn=0006-4971}}</ref>, decoy DNA<ref name=":7" /><ref>{{Cite journal |last=Soldevilla |first=Mario M. |last2=Pastor |first2=Fernando |title=Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy |url=http://dx.doi.org/10.1016/j.ymthe.2018.02.006 |journal=Molecular Therapy |volume=26 |issue=3 |pages=675–677 |doi=10.1016/j.ymthe.2018.02.006 |issn=1525-0016}}</ref> , antisense molecules<ref>{{Cite web |title=STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers |url=https://aacrjournals.org/clincancerres/article/24/23/5948/81103/STAT3-Inhibition-Combined-with-CpG |access-date=2023-09-11 |website=aacrjournals.org}}</ref><ref name=":11">{{Cite journal |last=Zhang |first=Bin |last2=Nguyen |first2=Le Xuan Truong |last3=Li |first3=Ling |last4=Zhao |first4=Dandan |last5=Kumar |first5=Bijender |last6=Wu |first6=Herman |last7=Lin |first7=Allen |last8=Pellicano |first8=Francesca |last9=Hopcroft |first9=Lisa |last10=Su |first10=Yu-Lin |last11=Copland |first11=Mhairi |last12=Holyoake |first12=Tessa L |last13=Kuo |first13=Calvin J |last14=Bhatia |first14=Ravi |last15=Snyder |first15=David S |title=Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia |url=https://www.nature.com/articles/nm.4499 |journal=Nature Medicine |language=en |volume=24 |issue=4 |pages=450–462 |doi=10.1038/nm.4499 |issn=1078-8956}}</ref> and others to selected immune cells.
+'''Marcin Kortylewski''' is a Polish American cancer researcher and [[Immunology|immunologist]]. He is currently professor of immuno-oncology at the [[Beckman Research Institute]] of the [[City of Hope National Medical Center]] in [[Duarte, California]].<ref name=":0">{{Cite web |date=2022-05-11 |title=Marcin Kortylewski, Ph.D. |url=https://www.cityofhope.org/marcin-kortylewski |access-date=2023-09-04 |website=City of Hope |language=en}}</ref> His research has shown that the STAT3 protein plays a role in protecting cancers from immune responses and contributes to resistance to therapies.<ref name=":5">{{Cite journal |last=Minton |first=Kirsty |title=Multi-tasking by STAT3 |url=https://www.nature.com/articles/nri2517 |journal=Nature Reviews Immunology |date=2009 |language=en |volume=9 |issue=3 |pages=149 |doi=10.1038/nri2517 |issn=1474-1741|doi-access=free }}</ref><ref name=":4">{{Cite journal |last1=Stewart |first1=C. Andrew |last2=Trinchieri |first2=Giorgio |title=Reinforcing Suppression Using Regulators: A New Link between STAT3, IL-23, and Tregs in Tumor Immunosuppression |url=https://linkinghub.elsevier.com/retrieve/pii/S1535610809000051 |journal=Cancer Cell |date=2009 |language=en |volume=15 |issue=2 |pages=81–83 |doi=10.1016/j.ccr.2009.01.008|doi-access=free }}</ref> Later he developed a two-pronged strategy for cancer immunotherapy using simultaneous [[STAT3]] inhibition and [[Toll-like receptor 9|TLR9]] immune stimulation.<ref>{{Cite journal |last1=Gantier |first1=Michael P |last2=Williams |first2=Bryan R G |title=siRNA delivery not Toll-free |url=https://www.nature.com/articles/nbt1009-911 |journal=Nature Biotechnology |date=2009 |language=en |volume=27 |issue=10 |pages=911–912 |doi=10.1038/nbt1009-911 |issn=1087-0156}}</ref><ref name=":6">{{Cite web |title=STAT3: the "Achilles" heel for AML? |url=https://ashpublications.org/blood/article/123/1/1/32121/STAT3-the-Achilles-heel-for-AML |access-date=2023-09-04 |website=ashpublications.org}}</ref><ref name=":7">{{Cite web |title=A STAT3 decoy lures AML out of hiding |url=https://ashpublications.org/blood/article/127/13/1628/34769/A-STAT3-decoy-lures-AML-out-of-hiding |access-date=2023-09-04 |website=ashpublications.org}}</ref> Kortylewski invented platform strategy for delivery of [[Oligonucleotide|oligonucleotides]], such as [[Small interfering RNA|siRNA]],<ref name=":9">{{Cite journal |last=Flemming |first=Alexandra |title=CpG–siRNA deals double blow to tumours |url=https://www.nature.com/articles/nri2665 |journal=Nature Reviews Immunology |date=2009 |language=en |volume=9 |issue=11 |pages=753 |doi=10.1038/nri2665 |issn=1474-1733|doi-access=free }}</ref> [[miRNA]],<ref>{{Cite web |title=MicroRNA immunomodulating therapeutics |url=https://ashpublications.org/blood/article/135/3/155/430078/MicroRNA-immunomodulating-therapeutics |access-date=2023-09-11 |website=ashpublications.org}}</ref> decoy DNA,<ref name=":7" /><ref>{{Cite journal |last1=Soldevilla |first1=Mario M. |last2=Pastor |first2=Fernando |title=Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy |url=http://dx.doi.org/10.1016/j.ymthe.2018.02.006 |journal=Molecular Therapy |date=2018 |volume=26 |issue=3 |pages=675–677 |doi=10.1016/j.ymthe.2018.02.006 |issn=1525-0016|doi-access=free |pmc=5911647 }}</ref> antisense molecules<ref>{{Cite web |title=STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers |url=https://aacrjournals.org/clincancerres/article/24/23/5948/81103/STAT3-Inhibition-Combined-with-CpG |access-date=2023-09-11 |website=aacrjournals.org}}</ref> and others to selected immune cells.
 == Education ==
+Kortylewski was born in [[Poznań|Poznań, Poland]]. He received his M.S. in biotechnology from [[Adam Mickiewicz University in Poznań|Adam Mickiewicz University]] and his Ph.D. in molecular biology from the [[Poznań University of Medical Sciences]] in Poznań, Poland.<ref name=":0" /><ref>{{Cite web |title=BioSpace Movers & Shakers, Sept. 10 |url=https://www.biospace.com/article/biospace-movers-and-shakers-sept-10/ |access-date=2023-09-22 |website=BioSpace |language=en-US}}</ref> Dr. Kortylewski completed postdoctoral training in cancer biology in Institute of Biochemistry at [[RWTH Aachen University|RWTH Aachen]] in Germany and later in tumor immunology at [[H. Lee Moffitt Cancer Center & Research Institute|H. Lee Moffitt Cancer Center]] in Tampa, Florida in USA.<ref name=":0" />
-{{no refs|section|date=September 2023}}
-Kortylewski was born in [[Poznań|Poznań, Poland]]. He received his M.S. in biotechnology from [[Adam Mickiewicz University in Poznań|Adam Mickiewicz University]] and his Ph.D. in molecular biology from the [[Poznań University of Medical Sciences]] in Poznań, Poland. Dr. Kortylewski completed postdoctoral training in cancer biology in Institute of Biochemistry at [[RWTH Aachen University|RWTH Aachen]] in Germany and later in tumor immunology at [[H. Lee Moffitt Cancer Center & Research Institute|H. Lee Moffitt Cancer Center]] in Tampa, Florida in USA.
 == Career ==
-Kortylewski began his post-graduate career in 1999 as a postdoctoral fellow in Iris Behrman’s lab in [[RWTH Aachen University|RWTH Aachen]]/Institute of Biochemistry chaired by Peter C. Heinrich. During his tenure there, he co-authored numerous research articles<ref>{{Cite web |title=kortylewski - Search Results - RWTH Publications |url=https://publications.rwth-aachen.de/search?ln=en&sc=1&p=kortylewski&f=&action_search=Search&c=FullTexts&c=100000&c=200000&c=300000&c=400000&c=500000&c=600000&c=700000&c=800000&c=510000-1&c=9000000&c=020000&c=010000&c=030000&c=000002&c=001000&c=hsbk000000&c=PublicReference&c=External&c=Authorities |access-date=2023-09-19 |website=publications.rwth-aachen.de |language=en}}</ref>.  Later, he moved to [[H. Lee Moffitt Cancer Center & Research Institute|H. Lee Moffitt Cancer Center]] in Tampa, Florida in USA to train with Richard Jove and Hua Yu. In 2005, he became Assistant Research Professor in the [[Beckman Research Institute]] of the [[City of Hope National Medical Center]] in [[Duarte, California]]. There, he became tenured faculty in 2010 and full professor at the Department of Immuno-Oncology in 2021.
+Kortylewski began his post-graduate career in 1999 as a postdoctoral fellow in Iris Behrman’s lab in [[RWTH Aachen University|RWTH Aachen]]/Institute of Biochemistry chaired by Peter C. Heinrich. During his tenure there, he co-authored numerous research articles.<ref>{{Cite web |title=kortylewski – Search Results – RWTH Publications |url=https://publications.rwth-aachen.de/search?ln=en&sc=1&p=kortylewski&f=&action_search=Search&c=FullTexts&c=100000&c=200000&c=300000&c=400000&c=500000&c=600000&c=700000&c=800000&c=510000-1&c=9000000&c=020000&c=010000&c=030000&c=000002&c=001000&c=hsbk000000&c=PublicReference&c=External&c=Authorities |access-date=2023-09-19 |website=publications.rwth-aachen.de |language=en}}</ref>  Later, he moved to [[H. Lee Moffitt Cancer Center & Research Institute|H. Lee Moffitt Cancer Center]] in Tampa, Florida in USA to train with Richard Jove and Hua Yu. In 2005, he became Assistant Research Professor in the [[Beckman Research Institute]] of the [[City of Hope National Medical Center]] in [[Duarte, California]]. There, he became tenured faculty in 2010 and full professor at the Department of Immuno-Oncology in 2021.{{cn|date=October 2023}}
-Kortylewski's research group focuses on understanding the mechanisms by which cancers evade the immune system and explores methods to enhance antitumor immune responses using DNA and RNA-based drugs.<ref name=":0" /><ref name=":2" /><ref name=":3" /> In early 2000s, he demonstrated that tumors turn off immune cell activity using a transcription factor, STAT3.<ref name=":4" /><ref>{{Cite journal |last=Kortylewski |first=Marcin |last2=Kujawski |first2=Maciej |last3=Wang |first3=Tianhong |last4=Wei |first4=Sheng |last5=Zhang |first5=Shumin |last6=Pilon-Thomas |first6=Shari |last7=Niu |first7=Guilian |last8=Kay |first8=Heidi |last9=Mulé |first9=James |last10=Kerr |first10=William G |last11=Jove |first11=Richard |last12=Pardoll |first12=Drew |last13=Yu |first13=Hua |title=Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity |url=https://www.nature.com/articles/nm1325 |journal=Nature Medicine |language=en |volume=11 |issue=12 |pages=1314–1321 |doi=10.1038/nm1325 |issn=1078-8956}}</ref><ref>{{Cite journal |last=Yu |first=Hua |last2=Kortylewski |first2=Marcin |last3=Pardoll |first3=Drew |date=2007-01-01 |title=Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment |url=https://www.nature.com/articles/nri1995 |journal=Nature Reviews Immunology |language=en |volume=7 |issue=1 |pages=41–51 |doi=10.1038/nri1995 |issn=1474-1733}}</ref><ref>{{Cite journal |last=Kortylewski |first=Marcin |last2=Xin |first2=Hong |last3=Kujawski |first3=Maciej |last4=Lee |first4=Heehyoung |last5=Liu |first5=Yong |last6=Harris |first6=Timothy |last7=Drake |first7=Charles |last8=Pardoll |first8=Drew |last9=Yu |first9=Hua |title=Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment |url=https://linkinghub.elsevier.com/retrieve/pii/S1535610808004376 |journal=Cancer Cell |language=en |volume=15 |issue=2 |pages=114–123 |doi=10.1016/j.ccr.2008.12.018 |pmc=2673504 |pmid=19185846}}</ref> His studies characterized STAT3 as a multitasking protein which prevents immune activation, while stimulating tumor vascularization and metastasis.<ref name=":6" /><ref>{{Cite journal |last=Gao |first=Chan |last2=Kozlowska |first2=Anna |last3=Nechaev |first3=Sergey |last4=Li |first4=Haiqing |last5=Zhang |first5=Qifang |last6=Hossain |first6=Dewan M.S. |last7=Kowolik |first7=Claudia M. |last8=Chu |first8=Peiguo |last9=Swiderski |first9=Piotr |last10=Diamond |first10=Don J. |last11=Pal |first11=Sumanta K. |last12=Raubitschek |first12=Andrew |last13=Kortylewski |first13=Marcin |date=2013-12-15 |title=TLR9 Signaling in the Tumor Microenvironment Initiates Cancer Recurrence after Radiotherapy |url=https://aacrjournals.org/cancerres/article/73/24/7211/584913/TLR9-Signaling-in-the-Tumor-Microenvironment |journal=Cancer Research |language=en |volume=73 |issue=24 |pages=7211–7221 |doi=10.1158/0008-5472.CAN-13-1314 |issn=0008-5472}}</ref><ref>{{Cite journal |last=Minton |first=Kirsty |title=Multi-tasking by STAT3 |url=https://www.nature.com/articles/nri2517 |journal=Nature Reviews Immunology |language=en |volume=9 |issue=3 |pages=149–149 |doi=10.1038/nri2517 |issn=1474-1733}}</ref> Kortylewski invented a two-pronged strategy for cancer immunotherapy combining STAT3 blocking using siRNA with triggering of immune receptor, Toll-like receptor 9 ([[TLR9]]) using CpG motif DNA.<ref>{{Cite journal |last=Kortylewski |first=Marcin |last2=Swiderski |first2=Piotr |last3=Herrmann |first3=Andreas |last4=Wang |first4=Lin |last5=Kowolik |first5=Claudia |last6=Kujawski |first6=Maciej |last7=Lee |first7=Heehyoung |last8=Scuto |first8=Anna |last9=Liu |first9=Yong |last10=Yang |first10=Chunmei |last11=Deng |first11=Jiehui |last12=Soifer |first12=Harris S |last13=Raubitschek |first13=Andrew |last14=Forman |first14=Stephen |last15=Rossi |first15=John J |title=In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses |url=https://www.nature.com/articles/nbt.1564 |journal=Nature Biotechnology |language=en |volume=27 |issue=10 |pages=925–932 |doi=10.1038/nbt.1564 |issn=1087-0156}}</ref><ref name=":8" /><ref>{{Cite web |last=slater |first=elias |date=2014-02-18 |title=Delivering a Triple-Knockout Punch to Prostate Cancer |url=https://www.pcf.org/news/delivering-a-triple-knockout-punch-to-prostate-cancer-a-novel-cancer-immunotherapy-approach-receives/ |access-date=2023-09-11 |website=Prostate Cancer Foundation |language=en-US}}</ref><ref name=":9" /><ref>{{Cite journal |last=Gantier |first=Michael P |last2=Williams |first2=Bryan R G |title=siRNA delivery not Toll-free |url=https://www.nature.com/articles/nbt1009-911 |journal=Nature Biotechnology |language=en |volume=27 |issue=10 |pages=911–912 |doi=10.1038/nbt1009-911 |issn=1087-0156}}</ref> Later on, he adopted the strategy as a platform for delivery of various oligonucleotide drugs to target oncogenic or immune regulators, such as STAT3<ref>{{Cite journal |last=Kortylewski |first=Marcin |last2=Moreira |first2=Dayson |title=Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities |url=http://link.springer.com/10.1007/s00262-017-1966-2 |journal=Cancer Immunology, Immunotherapy |language=en |volume=66 |issue=8 |pages=979–988 |doi=10.1007/s00262-017-1966-2 |issn=0340-7004}}</ref><ref>{{Cite web |title=STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers |url=https://aacrjournals.org/clincancerres/article/24/23/5948/81103/STAT3-Inhibition-Combined-with-CpG |access-date=2023-09-11 |website=aacrjournals.org}}</ref>, NF-kB or selected miRNAs<ref>{{Cite journal |last=Meyer |first=Sara E. |date=2020-01-16 |title=MicroRNA immunomodulating therapeutics |url=http://dx.doi.org/10.1182/blood.2019004106 |journal=Blood |volume=135 |issue=3 |pages=155–156 |doi=10.1182/blood.2019004106 |issn=0006-4971}}</ref><ref name=":10" /><ref name=":11" /> in human or mouse immune cells in vivo.
+Kortylewski's research group focuses on understanding the mechanisms by which cancers evade the immune system and explores methods to enhance antitumor immune responses using DNA and RNA-based drugs.<ref name=":0" /><ref name=":2">{{Cite web |last=Kortylewski |first=Marcin |title=Marcin Kortylewski |url=https://www.researchgate.net/profile/Marcin-Kortylewski/6 |access-date= |website=ResearchGate}}</ref><ref name=":3">{{Cite web |title=Marcin Kortylewski |url=https://scholar.google.com/citations?user=jSwLiswAAAAJ&hl=en |access-date=2023-09-04 |website=scholar.google.com}}</ref> In early 2000s, he demonstrated that tumors turn off immune cell activity using a transcription factor, STAT3.<ref name=":4" /> His studies characterized STAT3 as a multitasking protein which prevents immune activation, while stimulating tumor vascularization and metastasis.<ref name=":6" /><ref name=":5" /> Kortylewski invented a two-pronged strategy for cancer immunotherapy combining STAT3 blocking using siRNA with triggering of immune receptor, Toll-like receptor 9 ([[TLR9]]) using CpG motif DNA.<ref>{{Cite web |last=slater |first=elias |date=2014-02-18 |title=Delivering a Triple-Knockout Punch to Prostate Cancer |url=https://www.pcf.org/news/delivering-a-triple-knockout-punch-to-prostate-cancer-a-novel-cancer-immunotherapy-approach-receives/ |access-date=2023-09-11 |website=Prostate Cancer Foundation |language=en-US}}</ref><ref name=":9" /><ref>{{Cite journal |last1=Gantier |first1=Michael P |last2=Williams |first2=Bryan R G |title=siRNA delivery not Toll-free |url=https://www.nature.com/articles/nbt1009-911 |journal=Nature Biotechnology |date=2009 |language=en |volume=27 |issue=10 |pages=911–912 |doi=10.1038/nbt1009-911 |issn=1087-0156}}</ref> Later on, he adopted the strategy as a platform for delivery of various oligonucleotide drugs to target oncogenic or immune regulators, such as STAT3, NF-kB or selected miRNAs<ref>{{Cite journal |last=Meyer |first=Sara E. |date=2020-01-16 |title=MicroRNA immunomodulating therapeutics |url=http://dx.doi.org/10.1182/blood.2019004106 |journal=Blood |volume=135 |issue=3 |pages=155–156 |doi=10.1182/blood.2019004106 |issn=0006-4971|doi-access=free |pmc=6966931 }}</ref><ref name=":10">{{Cite journal |last1=Su |first1=Yu-Lin |last2=Wang |first2=Xiuli |last3=Mann |first3=Mati |last4=Adamus |first4=Tomasz P. |last5=Wang |first5=Dongfang |last6=Moreira |first6=Dayson F. |last7=Zhang |first7=Zhuoran |last8=Ouyang |first8=Ching |last9=He |first9=Xin |last10=Zhang |first10=Bin |last11=Swiderski |first11=Piotr M. |last12=Forman |first12=Stephen J. |last13=Baltimore |first13=David |last14=Li |first14=Ling |last15=Marcucci |first15=Guido |date=2020-01-16 |title=Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo |url=https://ashpublications.org/blood/article/135/3/167/429548/Myeloid-celltargeted-miR146a-mimic-inhibits |journal=Blood |language=en |volume=135 |issue=3 |pages=167–180 |doi=10.1182/blood.2019002045 |issn=0006-4971|doi-access=free |pmc=6966933 }}</ref><ref name=":11">{{Cite journal |last1=Zhang |first1=Bin |last2=Nguyen |first2=Le Xuan Truong |last3=Li |first3=Ling |last4=Zhao |first4=Dandan |last5=Kumar |first5=Bijender |last6=Wu |first6=Herman |last7=Lin |first7=Allen |last8=Pellicano |first8=Francesca |last9=Hopcroft |first9=Lisa |last10=Su |first10=Yu-Lin |last11=Copland |first11=Mhairi |last12=Holyoake |first12=Tessa L |last13=Kuo |first13=Calvin J |last14=Bhatia |first14=Ravi |last15=Snyder |first15=David S |title=Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia |url=https://www.nature.com/articles/nm.4499 |journal=Nature Medicine |date=2018 |language=en |volume=24 |issue=4 |pages=450–462 |doi=10.1038/nm.4499 |issn=1078-8956|pmc=5965294 }}</ref> in human or mouse immune cells in vivo.
-Kortylewski is a co-founder of a biomedical startup company, currently under the name Duet Biotherapeutics Inc., focused on advancing CpG-STAT3 inhibitors to clinical trials for cancer immunotherapy. <ref>{{Cite web |title=Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune |url=https://www.sec.gov/Archives/edgar/data/1772028/000110465921088231/tm2121272d1_ex99-1.htm |access-date=2023-09-11 |website=www.sec.gov}}</ref><ref>{{Cite web |last=Harris |first=William |date=2021-09-07 |title=Duet Therapeutics Appoints Marcin Kortylewski, Ph.D. as Senior Scientific Advisor |url=https://www.citybiz.co/article/135988/duet-therapeutics-appoints-marcin-kortylewski-ph-d-as-senior-scientific-advisor/ |access-date=2023-09-11 |website=citybiz |language=en-US}}</ref> He is an active contributor to the field of immune-oncology and oligonucleotide therapeutics, serving on scientific and editorial boards of journals and various organizations.<ref>{{Cite journal |last=Labant |first=MaryAnn |date=2014-06-15 |title=Therapeutic siRNA Interventions |url=http://dx.doi.org/10.1089/gen.34.12.01 |journal=Genetic Engineering &amp; Biotechnology News |volume=34 |issue=12 |pages=1, 18–19 |doi=10.1089/gen.34.12.01 |issn=1935-472X}}</ref><ref>{{Cite web |last=Cell |title=Molecular Therapy – Nucleic Acids editorial board contacts |url=https://www.cell.com/molecular-therapy-family/nucleic-acids/editorial-board}}</ref><ref>{{Cite web |date=2020-01-27 |title=Interview with Marcin Kortylewski, PhD |url=https://www.oligotherapeutics.org/interview-with-marcin-kortylewski/ |access-date=2023-09-11 |website=Oligonucleotide Therapeutics Society |language=en}}</ref><ref>{{Cite web |title=SITC Communications Committee |url=https://www.sitcancer.org/membership/volunteer2/volunteer/committees/communications |access-date=2023-09-11 |website=www.sitcancer.org |language=en}}</ref><ref>{{Cite web |title=Cancer Immunopathology and Immunotherapy Study Section |url=https://public.era.nih.gov/pubroster/preRosIndex.era?AGENDA=415955&CID=102302}}</ref>
+Kortylewski is a co-founder of a biomedical startup company, currently under the name Duet Biotherapeutics Inc., focused on advancing CpG-STAT3 inhibitors to clinical trials for cancer immunotherapy.<ref>{{Cite web |title=Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune |url=https://www.sec.gov/Archives/edgar/data/1772028/000110465921088231/tm2121272d1_ex99-1.htm |access-date=2023-09-11 |website=www.sec.gov}}</ref><ref>{{Cite web |last=Harris |first=William |date=2021-09-07 |title=Duet Therapeutics Appoints Marcin Kortylewski, Ph.D. as Senior Scientific Advisor |url=https://www.citybiz.co/article/135988/duet-therapeutics-appoints-marcin-kortylewski-ph-d-as-senior-scientific-advisor/ |access-date=2023-09-11 |website=citybiz |language=en-US}}</ref> He is an active contributor to the field of immune-oncology and oligonucleotide therapeutics, serving on scientific and editorial boards of journals and various organizations.<ref>{{Cite journal |last=Labant |first=MaryAnn |date=2014-06-15 |title=Therapeutic siRNA Interventions |url=http://dx.doi.org/10.1089/gen.34.12.01 |journal=Genetic Engineering & Biotechnology News |volume=34 |issue=12 |pages=1, 18–19 |doi=10.1089/gen.34.12.01 |issn=1935-472X}}</ref><ref>{{Cite web |last=Cell |title=Molecular Therapy – Nucleic Acids editorial board contacts |url=https://www.cell.com/molecular-therapy-family/nucleic-acids/editorial-board}}</ref><ref>{{Cite web |title=SITC Communications Committee |url=https://www.sitcancer.org/membership/volunteer2/volunteer/committees/communications |access-date=2023-09-11 |website=www.sitcancer.org |language=en}}</ref>
 == Awards ==
-In 2016, Kortylewski was a recipient of an Outstanding Young Investigator Award from [[American Society of Gene and Cell Therapy]], granted based on the contributions to the field of gene and cell therapy<ref>{{Cite web |title=Outstanding New Investigator Awards {{!}} ASGCT - American Society of Gene & Cell Therapy {{!}} ASGCT - American Society of Gene & Cell Therapy |url=https://asgct.org/awards/annual-meeting-awards/outstanding-new-investigator-awards |access-date=2023-09-04 |website=asgct.org}}</ref>. He received the award specifically for his work on “Eliminating Tumor Immune Defenses using Oligonucleotide Therapeutics”.
+In 2016, Kortylewski was a recipient of an Outstanding Young Investigator Award from [[American Society of Gene and Cell Therapy]], granted based on the contributions to the field of gene and cell therapy.<ref>{{Cite web |title=Outstanding New Investigator Awards {{!}} ASGCT – American Society of Gene & Cell Therapy {{!}} ASGCT – American Society of Gene & Cell Therapy |url=https://asgct.org/awards/annual-meeting-awards/outstanding-new-investigator-awards |access-date=2023-09-04 |website=asgct.org}}</ref> He received the award specifically for his work on “Eliminating Tumor Immune Defenses using Oligonucleotide Therapeutics”.
 == Patents ==
@@ Line 67: / Line 63: @@
 [[Category:Immunologists]]
 [[Category:Biotechnologists]]
+[[Category:Year of birth missing (living people)]]
+[[Category:Living people]]

Authority control databases
International	VIAF
National	Poland
Academics	ORCID